Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 13;224(7):1139-1146.
doi: 10.1093/infdis/jiaa083.

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine

Alemnew F Dagnew  1 , Nicola P Klein  2 , Caroline Hervé  3 , George Kalema  4 , Emmanuel Di Paolo  5 , James Peterson  6 , Bruno Salaun  5 , Anne Schuind  1
Affiliations

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine

Alemnew F Dagnew et al. J Infect Dis. .

Abstract

Background: Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time. We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients.

Methods: Adults aged ≥65 years who were previously vaccinated with ZVL ≥5 years earlier (n = 215) were group-matched with ZVL-naive individuals (n = 215) and vaccinated with RZV. Glycoprotein E (gE)-specific humoral and cell-mediated immune responses and the correlation between them, polyfunctional gE-specific CD4 T-cell responses, safety, and confirmed HZ cases were assessed.

Results: Through 12 months after dose 2, anti-gE antibody concentrations, gE-specific CD4 T-cell frequencies, and activation marker profiles were similar between groups. Safety outcomes were also similar. No HZ episodes were confirmed.

Conclusions: RZV induced strong humoral and polyfunctional cell-mediated immune responses that persisted above prevaccination levels through 1 year after dose 2 in adults aged ≥65 years irrespective of previous ZVL vaccination. The RZV safety profile was not affected.

Clinical trials registration: NCT02581410.

Keywords: Herpes zoster; Adjuvanted recombinant zoster vaccine; Live-attenuated herpes zoster vaccine; Persistence of immune response; Polyfunctionality; Safety.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Participant flow diagram. Abbreviations: ATP, according-to-protocol; HZ-NonVac, no previous vaccination with live-attenuated herpes zoster (HZ) vaccine before administration of adjuvanted recombinant zoster vaccine (RZV); HZ-PreVac, previous vaccination with live-attenuated HZ vaccine ≥5 years before administration of adjuvanted RZV; TVC, total vaccinated cohort; y, years.
Figure 2.
Figure 2.
Frequency of glycoprotein E (gE)–specific CD4 T cells expressing any combination of activation markers (according-to-protocol cohort for immunogenicity). A, Mean gE-specific CD4 T-cell frequencies. B, Relative mean gE-specific CD4 T-cell frequencies. C, Activation marker combinations (error bars represent interquartile ranges). Abbreviations: CD40L, CD40 ligand; HZ-NonVac, no previous vaccination with live-attenuated herpes zoster (HZ) vaccine before administration of adjuvanted recombinant zoster vaccine (RZV); HZ-PreVac, previous vaccination with live-attenuated HZ vaccine ≥5 years before administration of adjuvanted RZV; IFN-γ, interferon γ; IL-2, interleukin 2; mo, month(s); TNF-α, tumor necrosis factor α.
Figure 2.
Figure 2.
Frequency of glycoprotein E (gE)–specific CD4 T cells expressing any combination of activation markers (according-to-protocol cohort for immunogenicity). A, Mean gE-specific CD4 T-cell frequencies. B, Relative mean gE-specific CD4 T-cell frequencies. C, Activation marker combinations (error bars represent interquartile ranges). Abbreviations: CD40L, CD40 ligand; HZ-NonVac, no previous vaccination with live-attenuated herpes zoster (HZ) vaccine before administration of adjuvanted recombinant zoster vaccine (RZV); HZ-PreVac, previous vaccination with live-attenuated HZ vaccine ≥5 years before administration of adjuvanted RZV; IFN-γ, interferon γ; IL-2, interleukin 2; mo, month(s); TNF-α, tumor necrosis factor α.
See this image and copyright information in PMC

References

    1. Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013; 26:728–43. - PMC - PubMed
    1. Cohen JI. VZV: molecular basis of persistence (latency and reactivation). In: Arvin A, Campadelli-Fiume G, Mocarski E, et al, eds. Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge, United Kingdom: Cambridge University Press, 2007. - PubMed
    1. Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol 2010; 342:341–57. - PubMed
    1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open 2014; 4:e004833. - PMC - PubMed
    1. Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ. Annual incidence rates of herpes zoster among an immunocompetent population in the United States. BMC Infect Dis 2015; 15:502. - PMC - PubMed

Publication types

Associated data